Cat. No. 5233
Chemical Name: N-[2-[(4-Chlorophenyl)amino]-1-meth
Biological ActivityRho/SRF pathway inhibitor; stimulates apoptosis of a melanoma cell line overexpressing RhoC (A375M2). Suppresses Rho-dependent invasion of PC-3 prostate cancer cells in vitro and inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells. When used in combination with Retinoic acid, LY 294002 and Pyridone 6, it induces intermediate mesoderm differentiation from ESCs.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Mae et al (2010) Combination of small molecules enhances differentiation of mouse embryonic stem cells into intermediate mesoderm through BMP7-positive cells. Biochem.Biophys.Res.Commun. 393 877. PMID: 20171952.
Evelyn et al (2007) CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol.Cancer Ther. 6 2249. PMID: 17699722.
If you know of a relevant reference for CCG 1423 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses CCG 1423 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: CCG 1423, supplier, CCG1423, Rho, SRF, pathway, inhibitors, inhibits, intermediate, mesoderm, differentiation, ESC, embryonic, stem, cells, serum, response, factors, cancer, Tocris Bioscience, ESCs and iPSCs products